At a glance
ClinicalIndex Comparison RecordN/ACompleted· 70 enrolled
Drug / intervention
Erlotinib 150 mgdrug
Likely dose
Erlotinib 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Erlotinib (Tarceva® ) Therapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) , Subtype Adenocarcinoma, Who Have Good Performance Status (PS 0-1) - ELEMENT
In Brief
An observational study evaluating Erlotinib 150 mg for Non-Squamous Non-Small Cell Lung Cancer. Completed, enrolled 70 participants across 5 sites.
Detailed Summary
This multicenter, observational study will evaluate the efficacy and safety of Tarceva (erlotinib) in participants with locally advanced or metastatic adenocarcinoma non-small cell lung cancer and an ECOG performance status of 0-1. Eligible participants receiving Tarceva according to the Summary of Product Characteristics and local label will be followed for the duration of their treatment.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Squamous Non-Small Cell Lung Cancer
CountriesSerbia
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 2013
Enrollment StartMay 2013
Primary CompletionJan 2016
TodayJul 2026
First PostedApr 19, 2013
Enrollment StartMay 1, 2013
Primary CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 13.2 years ago
Interventions
Erlotinib 150 mgdrug